How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a net loss of $131.01 million. Despite setbacks, advancements in clinical trials and partnerships with ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results